Status:
COMPLETED
Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Lead Sponsor:
Dong-A ST Co., Ltd.
Collaborating Sponsors:
Meiji Seika Pharma Co., Ltd.
Conditions:
Moderate to Severe Chronic Plaque Psoriasis
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
This study is designed to evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of subcutaneously administered DMB-3115 in comparison with Stelara for treatment of moderate to severe chr...
Eligibility Criteria
Inclusion
- Patients who have a diagnosis of plaque-type psoriasis for at least 6 months.
Exclusion
- Patients with hypersensitivity to ustekinumab or any of the product excipients.
Key Trial Info
Start Date :
April 28 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 16 2022
Estimated Enrollment :
598 Patients enrolled
Trial Details
Trial ID
NCT04785326
Start Date
April 28 2021
End Date
November 16 2022
Last Update
January 18 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Central Sooner Research
Norman, Oklahoma, United States, 73071
2
Jordan Valley Dermatology Center
West Jordan, Utah, United States, 84088